NASDAQ:QNRX • US74907L4095
Past quarterly earnings results for QUOIN PHARMACEUTICALS LT-ADR (QNRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -6.71 | -5.08 | -32.19% | 59.21% | - | - | ||
| Q2 2025 | -6.28 | -7.56 | 16.91% | 53.99% | - | - | ||
| Q1 2025 | -6.50 | -6.19 | -5.04% | 83.27% | - | - | ||
| Q4 2024 | -12.25 | -16.42 | 25.40% | 83.17% | - | - | ||
| Q3 2024 | -16.45 | -17.61 | 6.60% | 75.90% | - | - | ||
| Q2 2024 | -13.65 | -21.78 | 37.32% | 81.69% | - | - | ||
| Q1 2024 | -38.85 | -27.13 | -43.19% | 72.79% | - | - | ||
| Q4 2023 | -72.80 | -82.65 | 11.91% | 57.72% | - | - | ||
| Q3 2023 | -68.25 | -97.18 | 29.77% | 82.71% | - | - | ||
| Q2 2023 | -74.55 | -100.67 | 25.95% | 94.52% | - | - | ||
| Q1 2023 | -142.80 | -121.10 | -17.92% | 86.40% | - | - | ||
| Q4 2022 | -172.20 | -264.75 | 34.96% | 95.44% | - | - | ||
| Q3 2022 | -394.80 | -577.48 | 31.63% | 71.64% | - | - | ||
| Q2 2022 | -1,360.80 | -1,320.92 | -3.02% | - | - | - | ||
| Q1 2022 | -1,050.00 | -1,419.08 | 26.01% | - | - | - | ||
| Q4 2021 | -3,775.28 | - | - | - | - | |||
| Q3 2021 | -1,392.30 | - | - | - | - | |||
| Q2 2021 | - | - | - | - | ||||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
QUOIN PHARMACEUTICALS LT-ADR (QNRX) last reported earnings on 11/6/2025.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, QUOIN PHARMACEUTICALS LT-ADR (QNRX) has beaten EPS estimates in 2 out of 4 releases.